Assessment of response to treatment with the PI3K/mTOR inhibitor BEZ235 with FLT PET in a tumor xenograft model

被引：0
|
作者：
Wanek, T. [1 ]
Fuereder, T. [2 ]
Pflegerl, P. [2 ]
Jaeger-Lansky, A. [2 ]
Hoeflmayer, D. [2 ]
Strommer, S. [2 ]
Mueller, M. [2 ]
Langer, O. [1 ]
Kuntner, C. [1 ]
Wacheck, V. [2 ]
机构：
[1] Austrian Inst Technol, Seibersdorf, Austria
[2] Med Univ Vienna, Vienna, Austria
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2010年 / 37卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
引用
收藏
页码：S298 / S299
页数：2
相关论文
共 50 条
  • [21] The PI3K/mTOR dual inhibitor BEZ235 suppresses proliferation and migration and reverses multidrug resistance in acute myeloid leukemia
    Deng, Lan
    Jiang, Ling
    Lin, Xiang-Hua
    Tseng, Kuo-Fu
    Liu, Yuan
    Zhang, Xing
    Dong, Rui-Hong
    Lu, Zhi-Gang
    Wang, Xiu-Ju
    ACTA PHARMACOLOGICA SINICA, 2017, 38 (03) : 382 - 391
  • [22] Dual PI3K/mTOR inhibitor BEZ235 as a promising therapeutic strategy against paclitaxel-resistant gastric cancer via targeting PI3K/Akt/mTOR pathway
    Chen, Dongshao
    Lin, Xiaoting
    Zhang, Cheng
    Liu, Zhentao
    Chen, Zuhua
    Li, Zhongwu
    Wang, Jingyuan
    Li, Beifang
    Hu, Yanting
    Dong, Bin
    Shen, Lin
    Ji, Jiafu
    Gao, Jing
    Zhang, Xiaotian
    CELL DEATH & DISEASE, 2018, 9
  • [23] The anti-tumor effects of dual PI3K/mTOR inhibitor BEZ235 and histone deacetylase inhibitor Trichostatin A on inducing autophagy in esophageal squamous cell carcinoma
    Wu, Ning
    Zhu, Yingfeng
    Xu, Xiao
    Zhu, Yongjun
    Song, Yang
    Pang, Liewen
    Chen, Zhiming
    JOURNAL OF CANCER, 2018, 9 (06): : 987 - 997
  • [24] Resistance of hepatocellular carcinoma to sorafenib can be overcome with co-delivery of PI3K/mTOR inhibitor BEZ235 and sorafenib in nanoparticles
    Wu, Binquan
    Li, Amin
    Zhang, Yinci
    Liu, Xueke
    Zhou, Shuping
    Gan, Huaiyong
    Cai, Shiyu
    Liang, Yong
    Tang, Xiaolong
    EXPERT OPINION ON DRUG DELIVERY, 2020, 17 (04) : 573 - 587
  • [25] A Phase Ib Study of the Dual PI3K/mTOR Inhibitor Dactolisib (BEZ235) Combined with Everolimus in Patients with Advanced Solid Malignancies
    Wise-Draper, Trisha M.
    Moorthy, Ganesh
    Salkeni, Mohamad A.
    Karim, Nagla Abdel
    Thomas, Hala Elnakat
    Mercer, Carol A.
    Beg, M. Shalaan
    O'Gara, Sue
    Olowokure, Olugbenga
    Fathallah, Hassana
    Kozma, Sara C.
    Thomas, George
    Rixe, Olivier
    Desai, Pankaj
    Morris, John C.
    TARGETED ONCOLOGY, 2017, 12 (03) : 323 - 332
  • [26] Dual PI3K/mTOR inhibitor BEZ235 exerts extensive antitumor activity in HER2-positive gastric cancer
    Yan Zhu
    Tiantian Tian
    Jianling Zou
    Qiwei Wang
    Zhongwu Li
    Yanyan Li
    Xijuan Liu
    Bin Dong
    Na Li
    Jing Gao
    Lin Shen
    BMC Cancer, 15
  • [27] BEZ235 Increases the Sensitivity of Hepatocellular Carcinoma to Sorafenib by Inhibiting PI3K/AKT/mTOR and Inducing Autophagy
    Cao, Weiya
    Liu, Xueke
    Zhang, Yinci
    Li, Amin
    Xie, Yinghai
    Zhou, Shuping
    Song, Li
    Xu, Ruyue
    Ma, Yongfang
    Cai, Shiyu
    Tang, Xiaolong
    BIOMED RESEARCH INTERNATIONAL, 2021, 2021
  • [28] BEZ235 increases sorafenib inhibition of hepatocellular carcinoma cells by suppressing the PI3K/AKT/mTOR pathway
    Li, Amin
    Zhang, Rongbo
    Zhang, Yinci
    Liu, Xueke
    Wang, Ruikai
    Liu, Jiachang
    Liu, Xinkuang
    Xie, Yinghai
    Cao, Weiya
    Xu, Ruyue
    Ma, Yongfang
    Cai, Wenpeng
    Wu, Binquan
    Cai, Shuyu
    Tang, Xiaolong
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2019, 11 (09): : 5573 - 5585
  • [29] Dual PI3K/mTOR inhibitor BEZ235 exerts extensive antitumor activity in HER2-positive gastric cancer
    Zhu, Yan
    Tian, Tiantian
    Zou, Jianling
    Wang, Qiwei
    Li, Zhongwu
    Li, Yanyan
    Liu, Xijuan
    Dong, Bin
    Li, Na
    Gao, Jing
    Shen, Lin
    BMC CANCER, 2015, 15
  • [30] A Phase Ib Study of the Dual PI3K/mTOR Inhibitor Dactolisib (BEZ235) Combined with Everolimus in Patients with Advanced Solid Malignancies
    Trisha M. Wise-Draper
    Ganesh Moorthy
    Mohamad A. Salkeni
    Nagla Abdel Karim
    Hala Elnakat Thomas
    Carol A. Mercer
    M. Shalaan Beg
    Sue O’Gara
    Olugbenga Olowokure
    Hassana Fathallah
    Sara C. Kozma
    George Thomas
    Olivier Rixe
    Pankaj Desai
    John C. Morris
    Targeted Oncology, 2017, 12 : 323 - 332
12345